Cargando…
Correction to: Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873746/ https://www.ncbi.nlm.nih.gov/pubmed/36473995 http://dx.doi.org/10.1007/s12094-022-03020-5 |
| _version_ | 1784877663407570944 |
|---|---|
| author | Cui, Yuzhong Huang, Wei Du, Feng Yin, Xiaoyang Feng, Lei Li, Baosheng |
| author_facet | Cui, Yuzhong Huang, Wei Du, Feng Yin, Xiaoyang Feng, Lei Li, Baosheng |
| author_sort | Cui, Yuzhong |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9873746 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98737462023-01-26 Correction to: Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study Cui, Yuzhong Huang, Wei Du, Feng Yin, Xiaoyang Feng, Lei Li, Baosheng Clin Transl Oncol Correction Springer International Publishing 2022-12-06 2023 /pmc/articles/PMC9873746/ /pubmed/36473995 http://dx.doi.org/10.1007/s12094-022-03020-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Cui, Yuzhong Huang, Wei Du, Feng Yin, Xiaoyang Feng, Lei Li, Baosheng Correction to: Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study |
| title | Correction to: Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study |
| title_full | Correction to: Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study |
| title_fullStr | Correction to: Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study |
| title_full_unstemmed | Correction to: Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study |
| title_short | Correction to: Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study |
| title_sort | correction to: therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873746/ https://www.ncbi.nlm.nih.gov/pubmed/36473995 http://dx.doi.org/10.1007/s12094-022-03020-5 |
| work_keys_str_mv | AT cuiyuzhong correctiontotherapeuticbenefitsofniraparibtosylateasradiosensitizerinesophagealsquamouscellcarcinomaaninvivoandinvitropreclinicalstudy AT huangwei correctiontotherapeuticbenefitsofniraparibtosylateasradiosensitizerinesophagealsquamouscellcarcinomaaninvivoandinvitropreclinicalstudy AT dufeng correctiontotherapeuticbenefitsofniraparibtosylateasradiosensitizerinesophagealsquamouscellcarcinomaaninvivoandinvitropreclinicalstudy AT yinxiaoyang correctiontotherapeuticbenefitsofniraparibtosylateasradiosensitizerinesophagealsquamouscellcarcinomaaninvivoandinvitropreclinicalstudy AT fenglei correctiontotherapeuticbenefitsofniraparibtosylateasradiosensitizerinesophagealsquamouscellcarcinomaaninvivoandinvitropreclinicalstudy AT libaosheng correctiontotherapeuticbenefitsofniraparibtosylateasradiosensitizerinesophagealsquamouscellcarcinomaaninvivoandinvitropreclinicalstudy |